Fenoglio, Chiara; Serpente, Maria; Arcaro, Marina; Carandini, Tiziana; Sacchi, Luca; Pintus, Manuela; Rotondo, Emanuela; ... Genetic FTD Initiative, GENFI; + view all Fenoglio, Chiara; Serpente, Maria; Arcaro, Marina; Carandini, Tiziana; Sacchi, Luca; Pintus, Manuela; Rotondo, Emanuela; Borracci, Vittoria; Ghezzi, Laura; Bouzigues, Arabella; Russell, Lucy L; Foster, Phoebe H; Ferry-Bolder, Eve; van Swieten, John C; Jiskoot, Lize C; Seelaar, Harro; Sánchez Valle, Raquel; Laforce, Robert; Graff, Caroline; Vandenberghe, Rik; de Mendonça, Alexandre; Tiraboschi, Pietro; Santana, Isabel; Gerhard, Alexander; Levin, Johannes; Sorbi, Sandro; Otto, Markus; Pasquier, Florence; Ducharme, Simon; Butler, Chris R; Ber, Isabelle Le; Finger, Elizabeth; Carmela Tartaglia, Maria; Masellis, Mario; Rowe, James B; Synofzik, Matthis; Moreno, Fermin; Borroni, Barbara; Rohrer, Jonathan D; Arighi, Andrea; Galimberti, Daniela; Genetic FTD Initiative, GENFI; - view fewer (2024) Inflammatory plasma profile in genetic symptomatic and presymptomatic Frontotemporal Dementia - A GENFI study. Brain, Behavior, and Immunity , 122 pp. 231-240. 10.1016/j.bbi.2024.08.030.

Text Fenoglio_Inflammatory plasma profile in genetic symptomatic and presymptomatic Frontotemporal Dementia_AAM.pdf - Accepted Version Access restricted to UCL open access staff until 20 August 2025. Download (631kB)

Abstract

BACKGROUND: Inflammation has been proposed as a crucial player in neurodegeneration, including Frontotemporal Dementia (FTD). A few studies on sporadic FTD lead to inconclusive results, whereas large studies on genetic FTD are lacking. The aim of this study is to determine cytokine and chemokine plasma circulating levels in a large cohort of genetic FTD, collected within the GENetic Frontotemporal dementia Initiative (GENFI). METHODS: Mesoscale technology was used to analyse levels of 30 inflammatory factors in 434 plasma samples, including 94 Symptomatic Mutation carriers [(SMC); 15 with mutations in Microtubule Associated Protein Tau (MAPT) 34 in Progranulin (GRN) and 45 in Chromosome 9 Open Reading Frame (C9ORF)72], 168 Presymptomatic Mutation Carriers (PMC; 34 MAPT, 70 GRN and 64 C9ORF72) and 173 Non-carrier Controls (NC)]. RESULTS: The following cytokines were significantly upregulated (P<0.05) in MAPT and GRN SMC versus NC: Tumor Necrosis Factor (TNF)α, Interleukin (IL)-7, IL-15, IL-16, IL-17A. Moreover, only in GRN SMC, additional factors were upregulated, including: IL-1β, IL-6, IL-10, IL-12/IL-23p40, eotaxin, eotaxin-3, Interferon γ-induced Protein (IP-10), Monocyte Chemotactic Protein (MCP)4. On the contrary, IL-1α levels were decreased in SMC compared with NC. Significantly decreased levels of this cytokine were also found in PMC, independent of the type of mutation. In SMC, no correlations between disease duration and cytokine and chemokine levels were found. Considering NfL and GFAP levels, as expected, significant increases were observed in SMC as compared to NC. These differences in mean values remain significant even when stratifying symptomatic patients by the mutated gene (P<0.0001). Considering instead the levels of NfL, GFAP, and the altered inflammatory molecules, no significant correlations emerged. CONCLUSION: We showed that inflammatory proteins are upregulated in MAPT and GRN SMC, with some specific factors altered in GRN only, whereas no changes were seen in C9ORF72 carriers. Notably, only IL-1α levels were decreased in both SMC and PMC, independent of the type of causal mutation, suggesting common modifications occurring in the preclinical phase of the disease.

Download activity - last month

Export as CSVJSONXML

Download activity - last 12 months

Export as JSONXMLCSV

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item